Objective: To evaluate the efficacy of olanzapine compared with risperidone in negative symptoms, after 1 year of treatment, in schizophrenic outpatients with prominent negative symptoms. Methods: This was a multicenter, randomized, monitored, openlabel, parallel, dose-flexible, 1-year study of outpatients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) with prominent negative symptoms (Scale for the Assessment of Negative Symptoms [SANS] summary score !10) previously treated with conventional antipsychotics. Patients were randomly assigned to treatment with an initial dose of olanzapine 10 mg/d or more (n = 120) or risperidone 3 mg/d or more (n = 115). The primary efficacy measure was the SANS summary score. Secondary efficacy measures included Scale for the Assessment of Positive Symptoms, Clinical Global Impression of Severity Scale, Calgary Depression Scale, and Social Functioning Scale. The response rate was defined as 30% or more of improvement in the SANS summary score. Results: The mean dose throughout the study was 12.2 mg/d (±5.8 mg/d) for olanzapine and 4.9 mg/d (±2.0 mg/d) for risperidone. At 1 year, olanzapine patients showed significantly higher improvement than risperidone patients on the SANS summary (P = 0.015) and on the affective flattening (P = 0.007) and avolition/apathy (P = 0.028) SANS subscales. There were also significant improvements in favor of olanzapine in the Scale for the Assessment of Positive Symptoms summary (P = 0.021), Clinical Global Impression of Severity (P = 0.008), and Social Functioning Scale total (P 0.001) scores. The response rate was greater (P = 0.001) in the olanzapine cohort (69.2%) than in the risperidone cohort (48.7%). Olanzapine patients reported less extrapyramidal side effects but a higher incidence of clinically important body weight increase than risperidone patients. Conclusions: Long-term treatment with olanzapine was associated with significantly better improvement in negative symptoms as compared with risperidone-treated schizophrenic outpatients with prominent negative symptoms. (J Clin Psychopharmacol 2006;26:238-249) 
T he focus of new drug development for the treatment of schizophrenia has been to obtain compounds with a broader efficacy profile, targeting negative, cognitive, and affective symptoms; and less likelihood to provoke extrapyramidal side effects. 1 The resulting second-generation antipsychotics (SGAs) have been extensively investigated in randomized, double-blind clinical trials comparing them to haloperidol, which have evidenced clear advantages in terms of both alleviating symptoms and fewer adverse effects. Nevertheless, recent meta-analyses have provided conflicting information about the advantages of firstgeneration antipsychotics and SGAs. In 1 study of 52 randomized trials, 2 the investigators found that lower doses of first-generation antipsychotics resulted in the same efficacy as the newer agents. In contrast to the previously mentioned meta-analyses, a meta-analysis of 142 clinical trials 3 concluded that the efficacy of clozapine, amisulpride, risperidone, and olanzapine was greater than that of firstgeneration antipsychotics; Leucht et al 4 also found that, as a group, new-generation drugs were more efficacious than low-potency antipsychotics, largely irrespective of the comparator doses used. When comparisons between SGAs were performed, the preponderance of data suggested no differences in overall efficacy. 3, 5 Differences in efficacy can also depend on what outcome measure is selected. For example, in a double-blind, randomized clinical trial comparing clozapine, risperidone, olanzapine, and haloperidol in patients with schizophrenia and a history of suboptimal response to first-generation antipsychotics who were hospitalized in state institutions, 6 clozapine and olanzapine showed superior reduction in psychopathology compared with haloperidol, but risperidone did not. However, in the same cohort and in comparison with haloperidol, improvement in cognition was seen among patients randomly assigned to receive either olanzapine or risperidone but not clozapine. 7 Clozapine retained a significant advantage in reducing hostility. 8 Recently, results from the National Institute of Mental Health-sponsored Clinical Antipsychotic Trial of Intervention Effectiveness study, 9 addressing questions such as ''how do the second-generation antipsychotics compare with a representative first generation antipsychotic?'' and ''what is the comparative effectiveness of SGAs?'' showed that although the majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons, olanzapine was the most effective in terms of the rates of discontinuation (primary end point of the study), meanwhile the efficacy of the other agents studied (the conventional antipsychotic perphenazine and the SGA drugs quetiapine, risperidone, and ziprasidone) appeared similar.
There has been a strong debate in the literature on whether antipsychotics can reduce negative symptoms and especially whether they can reduce primary negative symptoms and not just secondary negative symptoms. Primary negative symptoms belong to the core symptoms of schizophrenia, whereas secondary negative symptoms are the consequence of the following: (i) positive symptoms (eg, social withdrawal because of paranoid ideas), (ii) extrapyramidal effects (eg, motor retardation as an indicator of neuroleptogenic akinesia), (iii) depressive symptoms (eg, postpsychotic or pharmacogenic depression), or (iv) social understimulation (eg, hospitalization). 10 The efficacy of drug treatment of negative symptoms seems to be related to their pharmacological profile. The blockade of serotonin 5-HT 2A receptors or the preferential blockade of specific subtypes of dopamine receptors was hypothesized to be a relevant mechanism for the efficacy of SGAs in treating negative symptoms. 11 A review of the results of controlled studies assessing the efficacy of SGAs in treating negative symptoms 5, 12, 13 shows that, in general, these antipsychotics have a better effect than the classical antipsychotics on the negative symptoms of acute schizophrenia. Clinical studies on the efficacy of SGAs in patients who have chronic schizophrenia with stable predominant negative symptoms are generally still lacking. However, preliminary results support the assumption of a better effect of at least some of the SGAs, in particular, amisulpride.
14, 15 Tandon and Jibson 5 compared the efficacy in negative symptoms of 3 SGAs (risperidone, olanzapine, and quetiapine) across several randomized controlled clinical trials; all studies were 6 to 8 weeks in duration. No difference in the range and average improvement in negative symptoms (measured by means of Positive and Negative Syndrome Scale [PANSS] negative symptoms subscale) was observed across the 3 agents.
Risperidone and olanzapine separately have shown good tolerability and efficacy in the treatment of psychotic disorders. 16 -21 Although they share greater 5-HT 2A than D 2 antagonism, they differ in their profile of receptor binding affinities, 22 providing for in vivo different features. Four head-to-head prospective studies have compared these 2 agents, 22 -25 reporting that there is no solid evidence of shortterm substantial clinical superiority for either agent and that their respective advantages were predominantly determined by their side effect profile.
Regarding negative symptoms, the study by Tran et al 22 showed that olanzapine was superior to risperidone on the Scale for the Assessment of Negative Symptoms (SANS) score of negative symptoms. In a post hoc assessment performed in a subset of older patients (aged 50-65 years), olanzapine reduced PANSS negative subscale scores significantly more than did risperidone (P = 0.032). By the 28-week end point, olanzapine continued to maintain significantly greater reduction in baseline -to -end point PANSS negative scores (P = 0.032) and led to significantly greater reduction in scores on the SANS dimensions of affective flattening (P = 0.033) and alogia (P = 0.007). 26 One of the criticisms of the study by Tran et al was that the dosages of risperidone used (mean modal dose, 7.2 mg/d) were substantially higher than are common in the current clinical practice, which may result in a higher frequency of extrapyramidal symptoms (EPSs) and, in turn, possibly influence the score for negative symptoms. 27 Another double-blind, 1-year follow-up study comparing risperidone, olanzapine, and haloperidol in patients with schizophrenia showed significant improvement in PANSS negative scores by treatment with olanzapine (P = 0.04) but not with risperidone or haloperidol. However, between-groups pairwise comparisons showed that the treatment-group differences did not reach statistical significance. 28 However, in a short-term, head-to-head study, Conley and Mahmoud 29 found that there were no statistically significant differences between olanzapine and risperidone on any efficacy measure; in particular, there was no statistically significant difference with respect to the reduction of negative symptoms.
Limitations of theses studies include (i) none of these studies were performed in patients with predominantly negative symptoms, a relevant subset of patients with schizophrenia with poor prognosis in whom the confirmation of benefits of novel antipsychotics, as measured by the scales specifically addressing negative symptoms, is essential to draw conclusions about their relevance for the clinical practice; (ii) the fact that, in most studies of new antipsychotics, effects on negative symptoms were only investigated after the patient was hospitalized for an acute episode of schizophrenia with predominant positive symptoms; (iii) negative symptoms were not the primary end point in any of them; and (iv) efficacy data under naturalistic, clinician-acknowledged conditions have not been tested.
To answer more accurately the question of whether SGAs are also effective in schizophrenia with chronic negative symptoms, controlled studies should be carried out in such patients. 30 This is probably the most relevant clinical question because chronic negative symptoms clearly predict the course of the disease. 31 This article reports the results of a randomized, openlabel, long-term follow-up comparing the efficacy of olanzapine and risperidone in 250 stabilized outpatients with schizophrenia and with predominantly negative symptoms treated with conventional antipsychotics. The aim of this study is to try to answer a frequent real-world clinical dilemma: is it worthwhile (in terms of global symptoms, tolerability, and social functioning) to switch to SGAs the patients with schizophrenia treated with conventional antipsychotics, presenting chronic prominent negative symptoms and a limited autonomy but are otherwise clinically stabilized outpatients? Is there any difference (in terms of efficacy and/or tolerability) in switching to olanzapine or n 2006 Lippincott Williams & Wilkins risperidone? The design of the present study, encompassing a randomized allocation followed by a monitored open-label, dose-flexible treatment period with 1 of those drugs more extensively used in clinical practice (olanzapine or risperidone), provides scientific rigorousness (internal validity) at the time it strengthens the ability to generalization of results (external validity) by measuring the actual benefit obtained in the routine clinical setting. 32, 33 
MATERIALS AND METHODS

Design
This was a multicenter, randomized, open-label, flexibledose, fully monitored, parallel-group comparison of risperidone and olanzapine performed in 21 centers within Spain. Independent ethics committees reviewed and authorized the study in all participating sites before commencement.
Once the patients' (or their representative's) written informed consent to participate in the trial had been obtained, those patients fulfilling all the inclusion criteria and none of the exclusion criteria were randomized in the first visit. The treatment group assigned to each patient was established by a computerized system, so that all patients had the same probability of receiving olanzapine or risperidone (1:1 ratio). To assure the homogeneity of the assignment in each 1 of the centers, a randomized method, stratified by centers, by means of randomization blocks which were incorporated into the computerized randomization system, was used. Once the patient had been randomized to a treatment group, the study was carried out in an open manner. In this way, no treatment masking techniques were necessary. There was no washout period for previous antipsychotic and/or anticholinergic medications, although overlapping during the first month was allowed.
The study was implemented by a remote data entry process. All of the data were introduced with a computer program and reviewed by the program itself, by the Lilly staff and/or by an additional external partner hired to elaborate the study the statistical analysis. Data were 100% revised to look for any error or incongruity in it. Any problem that rose in this sense was discussed with the investigator. All those processes were followed to ensure that the database was complete, congruent, and safe.
Patient Population
Inclusion criteria included outpatients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of schizophrenia, a baseline summary score in the SANS summary 34 equal or higher than 10, and age ranging between 18 and 65 years; before randomization, if patients were in treatment with antipsychotics, they had to be first-generation ones. Participants must not have been hospitalized in psychiatry units within 3 months before enrolment, to secure that they were clinically stabilized patients.
Exclusion criteria included the presence of severe diseases other than schizophrenia deserving hospitalization within a term of 3 months, acute angle glaucoma, serious suicide risk, the use of forbidden concomitant pharmacotherapy such as psychotropic medications (other than benzodiazepines and anticholinergic drugs), treatment with an intramuscular depot antipsychotic within 2 months before enrolment, history or presence of unclassified seizures, leukopenia or jaundice, pregnant women, or being known to be sensitive or unresponsive to risperidone or olanzapine.
Treatment and Procedures
Both drugs were given once daily being the dose left at the discretion of the investigator at any moment. Although the investigators could use any dose, when feasible, it was recommended to start olanzapine at 10 mg/d and risperidone at 3 mg/d, with a progressive tapering of the previous antipsychotic medication, to minimize the risk of rapid destabilization. Investigators were allowed to prescribe whatever dose without ceiling. Biperiden (up to 6 mg/d) was allowed to treat, but not prevent, EPSs. This practice is in accordance with the accepted recommendations, and in addition, the need of using this drug provides additional data about tolerability. Benzodiazepines/hypnotics were also allowed up to an equivalent dose of 40 mg/d diazepam.
Patients were visited at monthly intervals up to week 24 and then every 2 months up to the end of randomized treatment, at week 48. Efficacy was assessed at weeks 8, 24, and 48 (or withdrawal). Primary efficacy measure was the SANS summary score. The SANS measures 5 dimensions of negative symptoms, each one covered by several independent items, scored using a range of 0 = none to 5 = severe, and one global or summary item. Each global or summary item score focuses in overall severity of the symptoms for that dimension. The SANS summary score is the sum of all 5 global items of SANS (ranges from 0 to 25). Secondary efficacy measures were the SANS composite score (the sum of the independent items of SANS ranging from 0 to 125) and the 5-item domain SANS scores. Positive symptoms were assessed with the Scale for the Assessment of Positive Symptoms (SAPS). 35 The overall severity of the illness was rated with the severity realm of the Clinical Global Impression of Severity (CGI-S) Scale. 36 Depressive symptoms were assessed with the Calgary Scale for depression in schizophrenia 37 and patient's functionality with the Social Functioning Scale (SFS). 38 Adverse events and body weight were recorded in all visits. Vital signs were measured at the same time points as the efficacy assessments. The EPSs were monitored systematically and assessed on all visits with regard to their incidence and severity, using the EPSs questionnaire from the UKU Scale 39 (dystonia, rigidity, hypokinesia/akinesia, tremor, akathisia, dyskinesia, and others, each one ranging from 1 = absent to 4 = severe). The date and reason for withdrawal, as well as the use of concomitant medication (benzodiazepines and anticholinergic drugs), were also recorded in the patient's case report form. Those data were used as pragmatic variables for effectiveness and tolerability.
Statistics
Statistical tests were performed at the 5%, 2-tailed significance level for all data analyzed. Only an intentionto-treat population, including that data from all randomized patients who were treated and who had at least 1 postbaseline assessment available, was defined for the analyses of effectiveness given the naturalistic disposition of this study. Between-group comparisons of change from baseline in continuous measures were analyzed with analysis of covariance (ANCOVA) with the treatment as the dependent variable and the factor center and baseline value as covariate in the model. The analysis for the primary end point (SANS summary score) was confirmatory. Analyses for secondary end points were exploratory. Between-group visitwise comparisons were analyzed by repeated-measures analysis of variance considering the factor center, visit, and treatmentby-visit interaction. Within-group changes from baseline were analyzed by a Wilcoxon test. Overall differences in categorical measures were analyzed by Mantel-Haenszel x 2 controlling for center. Changes from baseline were analyzed over imputed data (missing data estimated by carrying the last observation forward). Visitwise comparisons used observed data. The size of the study (125 patients per group) was determined to detect a minimum difference of 1.5 points in the reductions of the SANS summary score between groups, assuming a common SD of 4.0 points and a dropout rate of 10% and providing for a power of 80%.
In addition, a complex statistical model, a path analysis, was applied to determine whether a differential efficacy for negative symptoms (SANS summary score) favoring either olanzapine or risperidone was due to direct and/or indirect therapeutic effects. Improvement in negative, positive, depressive, and EPSs was measured by using change from baseline to end point (last observation carried forward [LOCF]) in SANS summary score, SAPS summary score, Calgary depression score, and UKU Scale. The direct effect on negative symptoms was defined as the treatment effect remaining after covarying for improvement with positive symptoms and depressive and EPSs, according to a linear regression.
RESULTS
Participant Characteristics and Disposition
A total of 250 subjects were randomized. Three of them terminated before receiving the study medication, and further 12 did not have any postbaseline efficacy data. Thus, the study comprises safety data from 247 subjects and effectiveness data from 235 subjects (Fig. 1) . Patients' baseline characteristics are summarized in Table 1 . Most participants were men (72.5%, n = 179), and their mean age was 36.3 years (SD, 10.6 years). There were no significant differences between both treatment groups in baseline characteristics, with the exception of body weight (olanzapine: mean, 73. ; P = 0.007), which were significantly lower in the olanzapine group.
A greater proportion of participants in the olanzapine group completed the study (75.2% [n = 87] in the olanzapine group and 66.1% [n = 76] in the risperidone group), although this difference was not significant (P = 0.2864). The mean duration of treatment was 287.3 days (SD, 110.5 days) in the olanzapine group and 273.7 days (SD, 117.4 days) in the risperidone group. The most frequent reason for premature discontinuation was consent withdrawal (37.5% [n = 27]; 27.3% [n = 9] in the olanzapine group and 46.2% [n = 18] in the risperidone group; P = 0.0501) ( Table 2 ).
Medication
At the study entry, 68.8% of patients were receiving antipsychotics (70.2% [n = 87] in the olanzapine group and 68.5% [n = 83] in the risperidone group), all of them firstgeneration antipsychotics. Moreover, 5.3% (n = 13) of the patients had previously received olanzapine, and 6.9% (n = 17) had previously received risperidone, although these patients had not shown efficacy or tolerability issues with these therapies in the past, and they did not receive these treatments within at least 3 months before the study entry.
The mean doses received by participants during the trial was 12. Table 3 ). The distribution of the mean daily doses throughout the trial were less than 5 mg of olanzapine received by 3.3% of the olanzapine participants (n = 4), 5 to 10 mg by 50.8% (n = 61), 10 to 15 mg by 23.3% (n = 28), 15 to 20 mg by 15.0% (n = 18), and more than 20 mg by 7.5% (n = 9); and less than 3 mg of risperidone received by 9.6% (n = 11) of the risperidone participants, 3 to 6 mg by 73.0% (n = 84), 6 to 9 mg by 14.8% (n = 17), and more than 9 mg by 2.6% (n = 3).
A significantly greater percentage of risperidone patients received anticholinergic medication (25.8% of olanzapine patients [n = 31] and 40.9% of the risperidone patients [n = 47]) during the study (P = 0.0144), but the proportion of patients receiving benzodiazepines was not significantly different between olanzapine-and risperidonetreated patients.
Efficacy
Negative symptoms
The primary efficacy measure was the SANS summary score. The SANS scores are summarized in Table 4 . Significant within-group improvements were observed from baseline to end of treatment in summary and composite SANS scores as well as on each score of its 5 domains in both treatment groups (P < 0.0001). Overall differences between treatments were significant in SANS summary (P = 0.0151) and SANS composite (P = 0.0183) scores at the end of treatment. Comparison of individual factors revealed greater improvement with olanzapine in affective flattening (P = 0.0065) and avolition/apathy (P = 0.0283) domains.
Because negative symptoms may be, to some extent, related to extrapyramidal side effects, 25 and anticholinergic medications used to treat them may affect cognitive function, a subgroup analysis to further examine the results in SANS among those patients receiving and not receiving anticholinergics was performed. Anticholinergic medication was received by significantly more risperidone patients (25.8% of olanzapine patients [n = 31] and 40.9% of the risperidone patients [n = 47]) during the study (P = 0.0144). Patients receiving anticholinergics in the risperidone group showed lesser improvements in both the SANS summary and composite scores compared with the respective within-group mean improvements, whereas this was not seen in the olanzapine group. On the other hand, there were developed several 2-way analysis of variance (ANOVA) models, with main effects treatment and use of anticholinergics, and the treatment-by-use interaction of anticholinergics for the changes (LOCF baseline) for the SANS summary and composite scores. Both analyses showed a nonsignificant interaction, suggesting that the differences between the treatment groups were consistent over the anticholinergics use. Use of anticholinergics was nonsignificant, suggesting similar mean improvements between those patients using and not using anticholinergics. Finally, the F test for treatment factor was significant, indicating that the improvements from baseline differ over the treatment groups.
The overall results of the path analysis performed are presented in Figure 2 . The improvement in the SANS summary score was statistically significant (ANCOVA, P = 0.0151), more favorable for those patients receiving olanzapine (5.93) than for those receiving risperidone (4.53). Furthermore, olanzapine showed a better efficacy on SAPS summary score and on other secondary variables. The question related to whether this superiority in the SANS summary score was due to a result on other variables effects or due to the existence of a relevant direct effect on SANS summary score seems to be of great importance.
The model used for the path analysis yielded a direct therapeutic effect of treatment with olanzapine relative to risperidone, accounting for 52.03% of the olanzapine advantage in improving negative symptoms (0.8065 of 1.55-point difference in SANS score), although this direct effect was not statistically significant (t = À1.56, P = 0.119). The other major contributor to negative symptom improvement was the indirect benefit of improved positive symptom as measured by the SAPS Scale, which accounted for 42.69% of the olanzapine advantage over risperidone in the model.
A higher proportion of patients treated with olanzapine showed clinical improvement, defined as a reduction of 30% or more in the SANS summary score, from baseline (69.2% of participants in the olanzapine group [n = 83] vs. 48.7% of participants in the risperidone group [n = 96]; P = 0.0014).
Other Efficacy Variables
Secondary efficacy measures included the SAPS, the CGI-S Scale, the Calgary Depression Scale, and the SFS. Within-group improvements from baseline in the SAPS summary and composite as well as on each score of its 4 domains were significant in both treatment groups ( P < 0.001). Overall differences between treatments were also significant in SAPS summary (P = 0.0207) and SAPS composite (P = 0.0115) scores, favoring olanzapine. In both treatment groups, the improvements on the CGI-S were significant (P < 0.0001), with significant between-group differences favoring olanzapine (P = 0.0082). Improvements in the Calgary Depression Scale were also significant in both groups (P < 0.0001), but between-group differences were negligible (P = 0.9745). Regarding the SFS total score, significant within-group improvements were observed from baseline to end of treatment in SFS total score (P = 0.0006) in the olanzapine group but not in the risperidone group; there were also significant between-group differences favoring olanzapine (P = 0.0028). The greatest betweengroup divergence in the SFS-related end points was found in the occupation/employment domain (P = 0.0024).
Safety and Tolerability Extrapyramidal Symptoms
The incidence of treatment-emergent EPS or worsening of previous EPS systematically recorded by means of the UKU-based questionnaire was significantly greater with risperidone (28. 
Other Adverse Events
More risperidone patients experienced at least 1 treatment-emergent adverse event (62.9% [n = 78] of olanzapine patients vs 72.4% [n = 89] of risperidone patients), but the difference between the groups was not statistically significant. The adverse events occurring in 5% of participants or more in either group are shown in Table 5 . The most frequently reported adverse events were anxiety, insomnia, and tremor. Tremor, akathisia, and sexual dysfunction were significantly more frequently reported in the risperidone group. Headache, weight increase, hypertension, and appetite increase were more frequently reported in the olanzapine group, but differences with the frequencies in the risperidone group were not significant.
Weight Gain
It has been mentioned that mean body weight at baseline was significantly greater in the risperidone group. Although greater with olanzapine, gains in body weight did not differ significantly between both treatment groups 69 kg] in the risperidone group; P = 0.5467). However, when study participants were categorized according to their changes from baseline in the body weight, an uneven distribution was found, with the proportion of patients who showed no change/decrease or increases lower than or equal to 5 kg in the risperidone group and the proportion of patients who showed increases between 5 and 10 kg or increases greater than 10 kg in the olanzapine group (P = 0.0192) being greater. In addition, the proportion of patients with a weight increase of 7% or greater was higher in the olanzapine group (40.7% [n = 35] vs. 17.3% [n = 13] in the risperidone group; P = 0.0012) (Fig. 3) . The evolution of weight gain was different between groups. Changes from baseline were significantly greater with olanzapine at weeks 8, 12, and 16, but not further, indicating that the gain occurred mainly in the first weeks of treatment with olanzapine, whereas risperidone produces a more sustained linear weight gain (Fig. 4) . The mean BMI was significantly greater in the risperidone group at baseline and also at weeks 8, 12, 16, 20, and 24 (Table 6 ).
DISCUSSION
To our knowledge, this analysis is the first that provides a direct, 1-year follow-up, head-to-head comparison Reduction from baseline to LOCF. k All within-group changes from baseline in both groups were significant ( P < 0.0001, Wilcoxon tests). { SANS composite score is the sum of all the items except the 5 global ratings (maximum score, 125).
of the 2 leading SGAs, risperidone and olanzapine, in a randomized, open-label study assessing their efficacy in negative symptoms as primary outcome in a sample of clinically stabilized outpatients with schizophrenia with prominent negative symptoms previously treated with firstgeneration antipsychotics. The findings indicate that both agents significantly improved psychopathology in this study population. However, as revealed by the SANS summary score, olanzapine procured a significantly higher improvement than risperidone in the primary measure of efficacy. Significant greater improvements with olanzapine were also seen in the SANS composite scores, which provide a complementary and more objective assessment, as well as in 2 individual factors of the scale (affective flattening and avolition/apathy domains). Interestingly, these results were not influenced by anticholinergic treatment in the olanzapine group, whereas they were so in patients treated with risperidone. Response rates in terms of negative symptoms were also higher in the olanzapine group. These results are consistent with those of other studies 22, 26 and with a recent meta-analysis of randomized clinical trials comparing olanzapine and risperidone, 40 which report significant differences in favor of olanzapine for the PANSS negative change from baseline, as well as for the PANSS total change, the PANSS general psychopathology change, and the proportion of patients responding with 40% and 50% or higher improvement in PANSS score over the longer term (>12 weeks). However, because most of the trials were carried out in patients experiencing both negative and positive symptoms during acute exacerbations of schizophrenic psychoses, the question arises whether only those negative symptoms that were secondary to positive symptoms were reduced. In addition, the overlap between negative symptoms of schizophrenia and extrapyramidal adverse effects and depression has to be taken into account.
As an alternative hypothesis to the direct effect of a drug on negative symptoms, the possibility that a drug reduces symptoms such as depression, akinesia, and sedation and thereby also reduces negative symptoms must be considered carefully. One possible approach to differentiating between direct and indirect drug effects on negative symptoms is to use statistical procedures. 10 Complex statistical approaches were not used until the mid-1990s. Möller et al 41 and Tollefson and Sanger 21 applied a complex statistical model, a path analysis, to the data of 2 doubleblind, random-assignment trials of risperidone (the former) 42 or olanzapine (the latter) 20 which assessed positive and negative symptoms and EPSs to determine whether risperidone/olanzapine had a more potent direct effect on negative symptoms than haloperidol. The aim was to determine whether a (direct) effect on negative symptoms remained after excluding the effects that were possibly caused through the reduction of positive symptoms and EPSs. The estimate from the path model showed in both cases that, even after statistical control for indirect effects on secondary negative symptoms, the SGAs improved negative symptoms to a greater extent than did haloperidol.
In the same manner, the path model estimated in this study tried to prove that the effect of olanzapine on SANS summary score reduction is due to a direct treatment effect. According to this model, olanzapine showed a greater total effect on SANS score than did risperidone, but this advantage was mainly due to a direct benefit of treatment, although it was not significant. We found that the change in SAPS score alone was insufficient to account for the observed improvement in negative symptoms. Likewise, the path analysis disclosed that the relatively low incidence of EPSs related to olanzapine when compared with those related to risperidone was only a minor indirect contributor to overall improvement in SANS score.
Although these results are promising, as Remington et al 43 remark, there are problems with such an approach. First, existing reports have not agreed on the identifiable secondary negative symptoms (''confounds'' that can be removed to allow for calculation of the direct effect of the drug on primary negative symptoms), with 1 study specifying only EPSs and positive symptoms, 41 whereas others have addressed these as well as depressive symptoms. 21, 44 A second difficulty involves the possibility that other sources of secondary negative symptoms exist Significantly more frequent in the risperidone group ( P = 0.0099).
z Significantly more frequent in the risperidone group ( P = 0.0357). (ie, neurocognitive impairment may be integrally related to negative symptoms).
Most of the path analyses reported up to date have been performed on data from efficacy studies, that is, from patients with acute episodes and therefore with preponderance of positive symptoms, with the subsequent bias in the selection of the sample used for a registration study. 43 The present study assures, as much as possible, that patients have a preponderance of negative symptoms (cutoff for SANS score and no hospitalizations in the last 3 months, which, in our setting, implies a very low probability of acute exacerbation).
Regarding other efficacy variables, included as secondary end points, there were also significant improvements in favor of olanzapine in positive symptoms (measured by the SAPS summary score) and social functioning (by means of the SFS total score).
The greater benefit observed with olanzapine over positive symptoms has to be considered with caution, as this evaluation was not the primary objective of this study. The recently published meta-analysis of randomized clinical trials comparing olanzapine and risperidone mentioned above, 40 as well as head-to-head, randomized clinical trial comparing both antipsychotics, could not find significant differences between olanzapine and risperidone for positive symptoms 23, 24 ; however, these results may provide some interesting data regarding the pharmacological approach to treat residual positive symptoms in chronic stabilized patients with schizophrenia (in contrast with acute positive symptoms).
From a clinical perspective, improvement in social functioning is the final objective of the global management of psychotic patients. Olanzapine-treated patients showed a significant benefit (not present in the risperidone group), and the greatest significant divergence occurred in the occupation/employment domain. This is an important pragmatic variable of effectiveness in the ''real world.'' Occupational insertion implies a relevant restoration of social abilities at the time it reduces dependence of patients.
The superiority of risperidone in relief of mood symptoms reported by Conley and Mahmoud 24 has not been observed in this study. Both drugs were equally highly effective to treat them as assessed by the Calgary Scale. However, the referenced authors assessed these symptoms by just the scoring of 1 PANSS item, whereas in this case, a specific instrument was used. On the other hand, this study recruited patients with some different clinical features associated with poorer prognosis and who were followed up for a longer term, facts that support the sensitivity of this assay.
Apart from the question of proven efficacy, the SGAs have another advantage of having no or a lower risk of extrapyramidal adverse effects, including parkinsonian adverse effects. Extrapyramidal adverse effects are known to induce a clinical picture similar to and often not distinguishable from schizophrenic negative symptoms. This problem is hidden in clinical trials by the administration of anticholinergics. The advantage of olanzapine over risperidone to cause less EPSs is confirmed in this study. Criticism was made to previous reports from head-to-head comparisons that also claimed this advantage 22, 23, 25 on the basis that they used risperidone doses higher than those selected for use in clinical practice. 24 The mean daily dose of risperidone received by participants in this study was 4.9 mg, and this was adjusted based on clinical symptoms, with 82.6% being the percentage of those receiving mean doses equal or lower than 6 mg/d throughout the study. Anticholinergic drugs have been temporally associated with impaired cognition and worsening of the patient's psychosis. 45 The affinity of olanzapine for muscarinic receptors has been proposed to account for the differences with risperidone in the potential for extrapyramidal side effects. Although muscarinic antagonism could mimic the effects of anticholinergics, these would be mitigated in the case of olanzapine, as anticholinergic medication was less prescribed and their use did not have a relevant impact over SANS scores within this group.
Certain SGAs are associated with greater weight gain liability than the high-potency typical antipsychotics. In a recent meta-analysis, 46 all antipsychotic drugs, with the exception of molindole and ziprasidone, were associated with some degree of weight gain after 10 weeks of treatment. In these short-term studies, SGAs, such as clozapine and olanzapine, were found to have the greatest potential to induce weight gain. However, the long-term outcome is relevant for the assessment of the risk/benefit ratio of therapeutic alternatives in a disease, such as schizophrenia, which requires chronic treatment. This study provides useful long-term data about this point. Although absolute weight increases in patients treated with olanzapine were higher than in those treated with risperidone, overall differences at the end of the 1-year follow-up were not significant. Despite olanzapine was associated with a quick weight gain after treatment onset, risperidone patients showed a slow but continuous weight gain. Thus, significant differences favoring risperidone were present after 8, 12, and 16 weeks but not later, as mean gain in the group receiving olanzapine stabilized afterward, whereas in the group treated with risperidone, weight continued rising.
This study contributes valuable data for the decisionmaking process in adjusting antipsychotic pharmacotherapy in outpatients with schizophrenia. Although both treatments have proven to be effective and acceptably safe in treating patients with schizophrenia achieving significant and clinically relevant improvements in psychopathology, it is worth to remark some useful nuances. First, participants were outpatients with prominent negative symptoms in a stable condition but still with a residual positive component after optimization of previous therapy, in all cases, firstgeneration antipsychotic agents. Second, this study was conducted under ''real world'' circumstances, without constraining the dose or the schedule of visits and without controlling treatment compliance beyond the standard in the routine care. Third, this was a long-term prospective study. Large, long-term, randomized studies in schizophrenia are overdue as grows the ambition of therapeutic goals, requiring complex and enduring end points for their evaluation.
The design of this study procured to minimize the drawbacks of previous head-to-head comparisons: this included a large sample size, a randomized allocation, a long follow-up (in fact, this is the longest randomized, head-tohead comparison between olanzapine and risperidone up to date), and a flexible dosing schedule extensive to initial doses and tapering of prior antipsychotic medications. In this way, it was conceived to complement the data yielded by olanzapine and risperidone clinical trials, providing valuable information for the clinician. The high retention rate achieved (69.36% of patients completed the study) may be a proof of that. Nevertheless, the design reflects several limitations to the interpretation of the results, such as open-label design, high number of dropouts due to unknown reasons, probable underreporting of adverse events compared with clinical trials, and so on. In addition, some aspects of the protocol could have been improved, such as not using a cutoff for the SAPS score above which a patient cannot be included, not using fasting blood glucose measurements to detect treatment-emergent diabetes with no clinical symptoms, or not including the most important pragmatic variables which allow to explore further the patients' personal autonomy (like the SFS does) but avoiding the disadvantages of an open-label design.
The most relevant contribution of this study, which replies to the question formulated in the aims of the study, is that stabilized patients with residual symptoms under conventional antipsychotic agents, such as the subjects enrolled in this study, would get further benefit upon switching to secondgeneration drugs, a worthwhile exercise for the clinician to optimize the management of schizophrenia.
CONCLUSIONS
This study combined the advantages of a randomized allocation and fully monitored with that of a long-term ''real world'' follow-up. Both risperidone and olanzapine were effective in the treatment of schizophrenia. This study included patients with prominent negative symptoms in whom olanzapine showed advantage over risperidone to improve negative symptoms. Olanzapine caused less extrapyramidal side effects but a quicker weight gain than did risperidone, although the mean increases in body weight with both drugs were comparable after 1 year. The advantage of olanzapine over risperidone to improve negative symptoms is promising, but further studies should be conducted to confirm these results.
